BIND Therapeutics and Synergy Pharmaceuticals Partner for Development of ACCURINS®

BIND Therapeutics, Inc. (NASDAQ: BIND) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced they have entered into a research collaboration to engineer ACCURINS® incorporating Synergy’s proprietary uroguanylin analogs to explore the potential targeting of guanylate cyclase-C (GC-C) receptors expressed on tumors, specifically GI malignancies.
According to the company’s press release:

Uroguanylin is a naturally occurring GI peptide and activator of the intestinal GC-C receptor, which is a known target for stimulating a variety of physiological responses. Plecanatide, Synergy’s lead uroguanylin analog for functional GI disorders, successfully completed phase 3 clinical trials for chronic idiopathic constipation (CIC) in 2015, and the Company recently filed a new drug application (NDA) for plecanatide to treat CIC. Synergy also recently announced positive data on its second uroguanylin analog, dolcanatide, in a phase 1b proof-of-concept study in ulcerative colitis patients.

Jonathan Yingling, Ph.D., chief scientific officer, BIND Therapeutics commented:

This collaboration represents another important advance as we develop ACCURINS® with the potential to target a broad range of cells with novel therapeutic payloads. The versatility of our platform is demonstrated by our wide range of collaborations and the ability to leverage our technology platform in a wide variety of applications. We believe the complementary technologies of Synergy and BIND have the potential to generate novel uroguanylin-based therapies that could have a profound impact on the treatment of diseases.

Click here to view the full press release.